ASHG 2019
Recent articles
Antidote to ‘poison’ DNA may treat lethal form of epilepsy
An experimental drug silences a DNA segment and seems to prevent seizures and death in a condition related to autism.
Antidote to ‘poison’ DNA may treat lethal form of epilepsy
An experimental drug silences a DNA segment and seems to prevent seizures and death in a condition related to autism.
Brain ‘organoids’ point to new drug target for fragile X syndrome
New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.
Brain ‘organoids’ point to new drug target for fragile X syndrome
New findings hint at why drugs that work in mouse models of fragile X syndrome have not been effective in people.
Massive project doubles list of genes tied to autism
The largest analysis of sequences from autistic people and their families implicates 184 genes in the condition — nearly doubling the previous estimate.
Massive project doubles list of genes tied to autism
The largest analysis of sequences from autistic people and their families implicates 184 genes in the condition — nearly doubling the previous estimate.
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.